Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma

por Lindholm, Kaleigh E., Forsberg, Peter A., Ewalt, Mark D.
Publicado 2021

Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis

por Lakritz, Stephanie, Forsberg, Peter A., Sherbenou, Daniel W., Mark, Tomer M.
Publicado 2022

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

por Keller, Alana L., Sherbenou, Daniel W., Forsberg, Peter A., Mark, Tomer M.
Publicado 2022

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations

por Davis, Lorraine, Walker, Zachary J., Ohlstrom, Denis, Stevens, Brett M., Forsberg, Peter A., Mark, Tomer M., Jordan, Craig T., Sherbenou, Daniel W.
Publicado 2022

CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts

por VanWyngarden, Michael J., Walker, Zachary J., Su, Yang, Perez de Acha, Olivia, Stevens, Brett M., Forsberg, Peter A., Mark, Tomer M., Matsui, William, Liu, Bin, Sherbenou, Daniel W.
Publicado 2023

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

por Perez de Acha, Olivia, Reiman, Lauren, Jayabalan, David S., Walker, Zachary J., Bosma, Grace, Keller, Alana L., Parzych, Sarah E., Abbott, Diana, Idler, Beau M., Ribadeneyra, Drew, Niesvizky, Ruben, Forsberg, Peter A., Mark, Tomer M., Sherbenou, Daniel W.
Publicado 2023

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study

por Lesokhin, Alexander, LeBlanc, Richard, Dimopoulos, Meletios A., Capra, Marcelo, Carlo‐Stella, Carmelo, Karlin, Lionel, Castilloux, Jean‐Francois, Forsberg, Peter, Parmar, Gurdeep, Tosikyan, Axel, Pour, Ludek, Ribrag, Vincent, Ribolla, Rossella, Abdallah, Al‐Ola, Le Roux, Nadia, Dong, Liyan, van de Velde, Helgi, Mayrargue, Laurent, Lépine, Lucie, Macé, Sandrine, Moreau, Philippe
Publicado 2023